The CorPath Vascular Robotic Program is the first and only robotic program for interventional cardiologists. Corindus is investing in next-generation technology and clinical research to explore new frontiers of vascular robotics, along with additional disease segments.
The PRECISION Study was a multicenter, post-market registry of robotic PCI using the CorPath 200 System. The purpose of the study was to collect data on the routine patterns of use, safety and effectiveness, including the clinical and technical performance of the CorPath 200 System, in the delivery and manipulation of coronary guidewires and stent/balloon catheters during PCI procedures.
Corindus has now launched the PRECISION GRX Study, a post-market registry to continue market surveillance of its second generation CorPath GRX System.
The pivotal, multi-center PRECISE trial demonstrated the safety and feasibility of the remote-controlled CorPath 200 System for use during PCI. The study met its clinical and technical endpoints, with the operator experiencing a significant reduction in radiation exposure. There were no reports of device-related complications and an overall clinical success rate of 97.6%. The average radiation exposure to the interventional cardiologist decreased by 95.2%, in contrast to levels reported during standard interventions.
1. Weisz G, et al. Safety and Feasibility of Robotic Percutaneous Coronary Intervention: PRECISE Study. J American College of Cardiol, 2013, Vol 61, No. 15: 1596-1600.